Also found in: Medical.
VEGFR-2Vascular Endothelial Growth Factor Receptor-2
References in periodicals archive ?
The membranes were incubated with VCAM-1, VEGFR-2, eNOS, and MMP-9 antibodies at 4[degrees]C overnight, followed by incubation with the corresponding secondary antibodies at room temperature for 2 h.
CHKA attenuated VEGFR-2 tyrosine kinase activity and VEGFR-2 signaling pathway
Slides were incubated for 30 minutes with a goat polyclonal antibody to human VEGF-165 (VEGF-A) (R&D Systems, Minneapolis, Minnesota) diluted 1:10, or a goat polyclonal antibody to human VEGFR-2 (KDR) (R&D Systems) diluted 1:15 in Dako antibody diluent.
Involvement of VEGFR-2 (kdr/flk-1) but not VEGFR-1 (flt-1) in VEGF-A and VEGF-C-induced tube formation by human microvascular endothelial cells in fibrin matrices in vitro.
VEGF165 modulates proliferation, adhesion, migration and differentiation of cultured human outer root sheath cells from central hair follicle epithelium through VEGFR-2 activation in vitro.
The researchers demonstrated that a biochemical process called methylation, which can regulate gene expression, also affects VEGFR-2, and this can lead to angiogenesis.
ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells.
Retinal pigment epitheliumchoroid levels of IkappaB-alpha, intercellular adhesion molecule (ICAM)-1, monocyte chemotactic protein (MCP)-1, interleukin (IL)-6, vascular endothelial growth factor (VEGF), VEGF receptor (VEGFR)-1, and VEGFR-2 were examined by Western blotting or ELISA.
VEGF-A binds to 2 related receptor tyrosine kinases, VEGF receptor 1 [VEGFR-1 (Flt-1)] and VEGFR-2 (KDR).
Sorafenib (Nexavar[R], Bayer Pharmaceuticals): inhibits FLT-3, KIT, VEGFR-2, VEGFR-3, PDGFR-[beta]
Similarly, by inhibiting the tyrosine kinase domains of VEGFR-1, VEGFR-2, and VEGFR-3 and other receptors (Raf, PDGFR-B, KIT, FLT-3, and RET), the oral drug Nexavar (Bayer) may compare favourably to antibodies targeting VEGF / VEGFR signalling.